Depicting a woman undergoing medical treatment with a focus on her head and brain, illustrating the potential risks of hormone therapy. The scene should evoke concern while remaining calm, set in a medical consultation room with brain scans in the background.
Hormonal treatments are widely used for various health conditions. However, new research suggests that certain hormonal therapies, specifically progestogens, may increase the risk of intracranial meningioma—a type of brain tumor. This finding could have significant implications for women undergoing hormone replacement therapy or other treatments involving progestogens.
“We found a notable association between prolonged progestogen use and the development of meningiomas,” the researchers stated. Their findings come from a large national case-control study, which examined the medical records of thousands of women. The researchers analyzed various forms of hormonal treatments and their effects on brain health, leading to these important conclusions.
The Progestogen Risk
According to the data, women using high doses of progestogens over extended periods had an increased risk of developing intracranial meningioma. “While the overall risk remains low, our study emphasizes the importance of careful monitoring,” said the lead researcher. The study involved detailed comparisons between those who developed meningiomas and those who did not, revealing a clear pattern of increased risk for those on hormonal treatments.
Impact on Medical Guidelines
This study has already started to influence discussions around treatment guidelines. Gynecologists, endocrinologists, and other healthcare professionals are now reconsidering the prescription of certain hormonal therapies. “We need to balance the benefits of progestogens with their potential risks,” said one of the study’s authors.
Progestogen Alternatives
As concerns grow, many healthcare providers are exploring alternatives to progestogens. “There are other treatment options available that may offer the same benefits without the increased risk of brain tumors,” the team noted. Alternatives could range from different hormonal treatments to non-hormonal approaches, each with its own set of advantages and risks.
Healthcare professionals are urged to consider individual risk factors, such as age, family history, and overall health, when prescribing progestogens. The study has opened up discussions on whether specific patient populations may benefit from different approaches to hormone therapy.
A Need for Further Research
Although the findings are compelling, the researchers caution that more research is necessary to fully understand the long-term risks of progestogen use. They also noted that the risk might be influenced by factors such as dosage, duration of treatment, and individual patient characteristics.
“We believe further studies will help clarify the full spectrum of risks associated with progestogen use,” said the lead researcher. As this area of research continues to develop, healthcare providers and patients alike are encouraged to stay informed and weigh the risks and benefits of hormonal treatments carefully.
Citation:
Roland N, Neumann A, Hoisnard L, Duranteau L, Froelich S, Zureik M, Weill A. Use of progestogens and the risk of intracranial meningioma: national case-control study. BMJ. 2023;384.
License:
This content is generated from the original article original article and it’s under Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
